Tharimmune (THAR) names interim CFO through Dec 31, 2025

Q: What did THAR announce in its 8-K?

Tharimmune appointed Sireesh Appajosyula as interim Chief Financial Officer.

Q: When does the interim CFO appointment take effect for THAR?

The Board approved the appointment on November 7, 2025.

Q: How long will THAR’s interim CFO serve?

The role is not to extend beyond December 31, 2025.

Q: What is Tharimmune’s trading symbol and exchange?

Tharimmune trades as THAR on The Nasdaq Stock Market LLC.

Q: Which item of the 8-K covers this change?

It is disclosed under Item 5.02 (director/officer changes and compensatory arrangements).

Tharimmune, Inc. appointed Sireesh Appajosyula as interim Chief Financial Officer.

Accepted by SEC EDGAR 11/10/2025 - 05:31 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Tharimmune, Inc. appointed Sireesh Appajosyula as interim Chief Financial Officer. The Board made the appointment on November 7, 2025, with the interim term set not to extend beyond December 31, 2025. The company stated that Mr. Appajosyula’s previously disclosed employment agreement with Tharimmune remains in effect. This is a leadership continuity move while the company finalizes its longer‑term finance leadership plans.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did THAR announce in its 8-K?

Tharimmune appointed Sireesh Appajosyula as interim Chief Financial Officer.

When does the interim CFO appointment take effect for THAR?

The Board approved the appointment on November 7, 2025.

How long will THAR’s interim CFO serve?

The role is not to extend beyond December 31, 2025.

Does the interim CFO have a current employment agreement with THAR?

Yes. The company notes his previously disclosed employment agreement remains in effect.

What is Tharimmune’s trading symbol and exchange?

Tharimmune trades as THAR on The Nasdaq Stock Market LLC.

Which item of the 8-K covers this change?

It is disclosed under Item 5.02 (director/officer changes and compensatory arrangements).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 7, 2025

THARIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41210		84-2642541
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

34 Shrewsbury Avenue, Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices, including zip code)

(732) 889-3111

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		THAR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 7, 2025, the Board of Directors of Tharimmune, Inc. (the “Company”) appointed Sireesh Appajosyula as interim Chief Financial Officer for a period not to extend beyond December 31, 2025. Mr. Appajosyula’s previously disclosed employment agreement with the Company remains in effect.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 10, 2025	Tharimmune, Inc.

	/s/ Mark Wendland
	Mark Wendland
	Chief Executive Officer

-3-

Source: View Original Filing on SEC EDGAR